A better way to develop immunotherapy

Discover our strategy
Close up image of a cell.
Close up image of a smiling women
image

We're developing better cancer and rheumatic disease treatment

Current treatments for certain cancers and rheumatic diseases benefit some patients, but remain costly and do not offer a cure. We are developing first-in-class immunotherapies that use mRNA delivery technology and highly specific llama-derived antibodies, with the potential to transform the field.  Our proprietary discovery program aims to make targeting malignant and immune cells in cancer and autoimmune diseases more accessible, precise, and effective.

A proven biotech team

We are immunotechnology entrepreneurs partnering with the National Research Council of Canada for pre-clinical development. Our expertise includes regulatory affairs, cancer immunotherapeutics, management of autoimmune diseases and product development.
Meet our team

Fund the future of immunotherapy

We invite institutional or qualified individual investors to support the clinical development of our product portfolio. Myellama offers an early-stage investment opportunity for angel investors, venture philanthropy, or early-stage venture firms focused on social impact and value creation.
See investment opportunity 
Back-facing female presenting person in white lab coat holding a syringe.
Myellama TherapeuticsContact us:bzanke@myellama.com1 (647) 287-8070
Subscribe to email updates.
Privacy Policy